证券代码：300015 证券简称：爱尔眼科 公告编号：2026-004 爱尔眼科医院集团股份有限公司 | | 是否为 控股股 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东或第 | | 占其所 | 占公 | | 是否 | | | | | | 股东 | 一大股 | 本次质押 | 持股份 | 司总 | 股份性质 | 为补 | 质押起 | 质押到期 | 质权人 | 用途 | | 名称 | | 股数（股） | | 股本 | | 充质 | 始日 | 日 | | | | | 东及其 | | 比例 | | | | | | | | | | 一致行 | | | 比例 | | 押 | | | | | | | 动人 | | | | | | | | | | | | | | | | | | | | 国泰海 | | | 陈邦 | 是 | 62,000,000 | 4.29% | 0.66% | 流通股（高 | 否 | 2026年 1 | 2027 年 1 | 通证券 | 质押 | | | | | | ...

Group 1: Industry Overview and Challenges - The domestic ophthalmology medical service industry is gradually emerging from an adjustment period, with increasing demand driven by national policies and a large population base [1][2] - The low penetration rate of various sub-specialties in ophthalmology, coupled with high myopia rates among youth and aging-related eye diseases, presents significant growth opportunities [1][2] Group 2: Business Strategy and Development Plans - The company has initiated a "three-year攻坚" plan focusing on solidifying its foundation, enhancing operational efficiency, and promoting sustainable high-quality development [3][4] - Key strategies include deepening internal growth, advancing technological innovation and digital transformation, consolidating talent and research advantages, and adapting to market and policy changes [3][4][5] Group 3: International Expansion - The company has established a presence in Europe, Southeast Asia, and the United States, with overseas business contributing approximately 13% to total revenue [6] - The international strategy emphasizes adapting to local market conditions and regulatory environments while leveraging domestic expertise in ophthalmology [6] Group 4: Technological Innovation and Research - The company is exploring the application of cutting-edge technologies in visual reconstruction and eye care through strategic partnerships, although these initiatives are still in early stages and unlikely to impact short-term performance [7]

Group 1 - The core viewpoint of the news highlights the positive momentum in the medical innovation sector, driven by the National Healthcare Security Administration's initiatives to support pricing for innovative medical technologies [1][2] - The China Securities Index for medical and medical device innovation (931484) shows mixed performance among its constituent stocks, with notable gains from companies like Yingke Medical and New Horizon [1] - The Medical Innovation ETF (516820) has seen significant net inflows, totaling 51.78 million yuan over four days, indicating strong investor interest in the sector [1] Group 2 - CITIC Securities anticipates that the expansion of the National Healthcare Security Administration's pricing directory will facilitate faster national pricing and hospital admission processes for innovative medical devices, addressing previous challenges in the market [2] - The index comprises 30 publicly listed companies with strong profitability and growth potential, reflecting the overall performance of the medical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the index account for 63.75% of its total weight, including major players like WuXi AppTec and Mindray Medical [2]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判 ...

Group 1 - The core viewpoint is that Zhao Bei, a fund manager, oversees seven funds, with the best quarterly performance being a decline of 11.44% for the Industrial Bank Pension Industry Stock A fund by the end of Q4 2025 [1] - During Zhao Bei's tenure as the manager of the Industrial Bank Healthcare Stock fund, the cumulative return was 192.7%, with an average annualized return of 10.08% [1] - The fund had 95 instances of stock adjustments, achieving a profit in 65 cases, resulting in a win rate of 68.42% [1] Group 2 - A notable stock adjustment example is the investment in Yingke Medical, which was bought in Q1 2020 and sold in Q1 2021, yielding an estimated return of 812.18% during the holding period, with a revenue growth of 17.37% from 2020 to 2021 [2] - Another example is the investment in Lepu Medical, purchased in Q4 2015 and sold in Q3 2020, which resulted in an estimated return of 99.44%, while the net profit increased by 245.93% from 2015 to 2020 [3] - A less successful case involved Aier Eye Hospital, bought in Q2 2021 and sold in Q2 2024, resulting in an estimated return of -63.63%, despite a net profit growth of 53.06% from 2021 to 2024 [4]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

截至2026年1月21日 13:11，中证医药及医疗器械创新指数(931484)上涨0.03%，成分股特宝生物上涨 3.38%，甘李药业上涨2.24%，英科医疗上涨1.70%，康龙化成上涨1.23%，大博医疗上涨1.16%。医疗创 新ETF(516820)多空胶着，最新报价0.37元。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index rising by 0.55% and several constituent stocks showing significant gains [1] - The Medical Innovation ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.0262 million and a total of 11.2443 million, averaging 3.7481 million per day [1] - The National Healthcare Security Administration issued a guideline aimed at standardizing pricing for surgical and treatment auxiliary services, promoting a shift from traditional treatment to precision medicine [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, accounting for 63.75% of the total index weight [2]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market this week, with a 0.68% decline in the biotechnology sector compared to a 0.03% increase in the overall A-share market [1] - The report highlights the successful listing of Rebio Biotech on the Hong Kong Stock Exchange, focusing on the small RNA industry and its potential [2] - Rebio Biotech has established a proprietary delivery platform, RiboGalSTAR, and has entered into commercialization partnerships valued at over $2 billion [2] - The core asset RBD4059, targeting FXI, is currently in clinical phase 2a studies in Sweden, showing promise in treating thrombotic diseases [2][21] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the Shanghai Composite Index decreased by 0.57%. The biotechnology sector saw a decline of 0.68% [1][26] - Within the biotechnology sector, chemical pharmaceuticals fell by 2.40%, while medical services rose by 3.29% [1][26] Company Overview - Rebio Biotech focuses on small RNA drug development, with seven products in clinical research, four of which are in phase 2 trials [2][9] - The company has a strong management team with extensive experience in drug development and production [16][18] Financial Projections - The report provides earnings forecasts for key companies, with Rebio Biotech's core asset RBD4059 showing significant potential in the thrombotic disease market [3][21] - The report recommends investment opportunities in the CXO sector and highlights the clinical progress of innovative drugs overseas [2][36] Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 38.70x, compared to 22.18x for the overall A-share market [31] - Specific sub-sectors show varying P/E ratios, with chemical pharmaceuticals at 47.60x and medical services at 36.15x [31]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market, with a TTM P/E ratio of 38.70x, which is at the 84.85th percentile of the past five years [1][31] - The report highlights the recent IPO of RiboBio, a leading company in the small RNA drug development sector, which has established a proprietary delivery platform, RiboGalSTAR, focusing on cardiovascular, metabolic, renal, and liver diseases [2][9] - RiboBio has seven products in clinical research, with four advancing to Phase II trials, demonstrating the effectiveness and safety of its delivery system [2][17] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the biopharmaceutical sector declined by 0.68%, with chemical pharmaceuticals dropping by 2.40% [1][26] - The report notes significant individual stock movements, with some companies experiencing substantial gains and others facing steep declines [26][30] Company Focus: RiboBio - RiboBio has formed strategic partnerships with Boehringer Ingelheim and Qilu Pharmaceutical, with a total transaction value exceeding $2 billion, validating the platform's value [2][17] - The core asset, RBD4059, is in Phase IIa trials in Sweden for treating thrombotic diseases, showing promising results in reducing thrombus formation without increasing bleeding risk [2][21] - RBD4059's clinical data indicates a significant reduction in FXI activity, with a maximum percentage change of 91.6% at the highest dosage [22] Investment Recommendations - The report suggests focusing on investment opportunities in the CXO sector and the clinical progress of innovative drugs overseas [2] - Specific companies recommended for investment include Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [3][36]